Vietnam Treats COPD at Commune Clinics Without Spirometers
Vietnam's commune health stations are the first point of care for most people with chronic breathlessness, yet few have a working spirometer. Clinicians diagnose COPD from symptom checklists and peak flow readings, a practice that diverges sharply from international guidelines and misclassifies many patients. This piece explains what the evidence requires, what actually happens at commune level, and which practical steps could narrow the gap.
The Spirometer Gap in Vietnam
Vietnam's public health system is organised in tiers. Commune health stations sit closest to patients, district hospitals above them, and provincial or central hospitals at the top. COPD is supposed to be managed at the commune level whenever possible, which keeps travel and cost down for patients who are often older, poorer, and living in rural provinces.
The problem is equipment. Spirometers exist mainly at district hospitals and above. A commune station may have no device at all, or one that has been broken, uncalibrated, or out of consumables for months. Staff rotate, and no one owns maintenance. The result is that the tier expected to diagnose COPD is the tier least equipped to do so.
For patients, the arithmetic is simple. A spirometry appointment can mean a motorbike ride of an hour or more to a district facility, a wait, and a return trip for results. Many do not go. Some are told they have chronic bronchitis or simply given a course of antibiotics and sent home.
Rural provinces in the Mekong Delta and northern highlands face the steepest barriers. A commune health station there might serve several thousand people with a staff of three to five, and the nearest district hospital with a functioning spirometer could be 30 to 60 kilometres away over roads that flood or turn to mud in the rainy season. For a patient with advanced COPD, that journey can be physically exhausting and financially crippling.
What Evidence Says About Diagnosis
Spirometry measures how much air a person can exhale and how fast. The key value is the ratio of forced expiratory volume in one second to forced vital capacity, written FEV1/FVC. A ratio below a commonly used threshold after a bronchodilator supports a COPD diagnosis. This is the standard the Global Initiative for Chronic Obstructive Lung Disease, or GOLD, describes in its reports, and it is what most national guidelines echo.
The requirement for post-bronchodilator testing matters. A single pre-bronchodilator reading can look obstructive in someone whose airways are simply reacting to something reversible, which is more typical of asthma. Without the bronchodilator step, the same number can point to the wrong disease.
Symptoms alone are a weak substitute. Cough, sputum, and breathlessness overlap heavily with asthma, bronchiectasis, heart failure, and tuberculosis sequelae. Studies from several countries have found both under-diagnosis, where people with clear obstruction are missed, and over-diagnosis, where people labelled with COPD do not meet spirometric criteria on testing. The pattern is consistent enough that symptom-only diagnosis is not considered adequate anywhere with the resources to do better.
Primary care settings in high-income countries that rely on symptoms alone report misclassification rates that can exceed 30 to 40 percent when patients are later tested. The direction of error varies: some patients with asthma receive a COPD label and unnecessary inhaled corticosteroids, while others with true COPD are dismissed as having a smoker's cough or recurrent bronchitis. This is not a problem unique to Vietnam, but the absence of spirometry at the first point of contact makes it more likely.
Clinical Reality at Commune Level
What commune clinicians actually have is a stethoscope, a history, and sometimes a peak flow meter. Peak flow measures how fast a person can blow air out, but it captures only part of the picture. It cannot distinguish fixed obstruction from reversible narrowing, so it cannot reliably separate COPD from asthma. A low peak flow reading is compatible with both.
Equipment is only one barrier. A spirometer costs money to buy, calibrate, and keep supplied with disposable mouthpieces and filters. In a station with a small budget and competing priorities, a device that needs regular attention tends to lose. Training is the other half. Good spirometry depends on coaching the patient, judging effort, and recognising an unacceptable manoeuvre. A device without a trained operator produces numbers that look authoritative and are not.
This site has argued in a related piece that specialist referral caps at primary clinics shift complex decisions onto generalists without always shifting the tools. Vietnam's respiratory gap has a similar shape. The task is delegated; the means are not.
Consequences for Patients and Care
Delayed diagnosis has a cost. COPD is progressive, and the interventions that change its trajectory, mainly smoking cessation and inhaled bronchodilators, work best when started earlier. A patient who spends two years on repeated antibiotic courses for presumed recurrent bronchitis loses that window.
Misprescribing runs in both directions. Inhaled corticosteroids are indicated for some COPD patients, particularly those with frequent exacerbations or features suggesting asthma overlap, but they are not first-line for everyone. When asthma and COPD are confused, patients may receive steroids they do not need, with added risk of pneumonia and oral thrush. Others who need inhaled therapy get none.
Smoking cessation advice is delivered inconsistently. It is the single most effective intervention for slowing COPD, and it depends on repetition and follow-up that a busy commune station may not have time to provide. Referral pathways are also unclear. A clinician who suspects severe disease may not know which district hospital accepts respiratory referrals, what documentation is needed, or whether the patient can afford the trip.
Exacerbations are another pressure point. When a patient with unrecognised COPD presents with worsening breathlessness, the default response is often antibiotics and sometimes oral steroids, without confirming the underlying diagnosis. This can relieve symptoms temporarily but does nothing to address the long-term decline in lung function. Each exacerbation also increases the risk of the next, creating a cycle that a correct diagnosis and maintenance inhaler could interrupt.
Steps Toward Better Diagnosis
Portable spirometers have become cheaper and more robust, and some models are designed for primary care with simplified quality checks. Pairing a device with a structured training programme, rather than handing it over alone, is what makes the difference. A related piece on Ghana's insurance coverage for diabetes drugs makes a comparable point about equipment without a funding line behind it.
Task-shifting is a realistic option. Commune nurses can be trained to perform spirometry to a defined standard, with a small number of supervised sessions and periodic refresher training. Several countries have taken this route for asthma and COPD, and the evidence supports trained non-physician operators when quality control is in place.
Telemedicine can support interpretation. A nurse uploads a flow-volume curve; a district or provincial clinician reviews it and confirms or questions the reading. This keeps the diagnostic decision with someone who sees enough cases to stay sharp, without requiring the patient to travel.
Quality control deserves its own budget line. Calibration checks, mouthpiece supply, and a simple logbook of acceptable and unacceptable manoeuvres prevent a device from quietly drifting out of use. Vietnam's tuberculosis programme already runs a network of smear and, increasingly, molecular testing with specimen transport and supervision. Integrating spirometry into that existing structure, rather than building a parallel one, is the most plausible route to scale.
The trade-off is real. A district hospital physician might object that task-shifted spirometry without close supervision produces unreliable numbers that then drive treatment. That objection has merit where training and audit are thin. The counter is that symptom-only diagnosis is already unreliable, and the choice is between two imperfect options, not between imperfect and perfect.
If you work in a commune health station, ask your district respiratory focal point whether a portable spirometer is available for loan and who calibrates it. If you are a district clinician, check whether your referral form specifies the spirometry values you need, so commune staff know what to send. If you manage a provincial programme, add a calibration and consumables line to the budget instead of treating the device as a one-off purchase. If you are a patient with a COPD label and no spirometry result on file, ask at your next visit whether the diagnosis was confirmed by testing. And if you train health workers, include a supervised spirometry session in the curriculum rather than a lecture alone.
This article is informational and does not constitute personal medical advice. Diagnosis and treatment decisions should be made with a qualified clinician who can examine you and review your test results.
